Clinical trials
Nephropathy clinical trials
Below are recruiting nephropathy clinical trials, each written for real people, not researchers. We’re tracking 147 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06065852Recruiting
National registry for rare kidney diseases
This study creates a registry to collect health information from people with rare kidney diseases. It aims to improve understanding and future treatments by tracking patient experiences.
Bristol, South WestAges Any age - NCT07347769Recruiting
BK virus risk study in kidney transplant patients
This study looks at the type and genetic makeup of BK virus in kidney transplant patients and their donors. It aims to find patients at higher risk for a kidney infection caused by the virus, which could help improve monitoring and treatment.
GrenobleAges 18 years+ - NCT07498335RecruitingPhase 3
Atrasentan for children with IgA nephropathy
This trial tests an experimental medicine called atrasentan for children aged 2 to under 18 with IgA nephropathy, a kidney disease. The study aims to see if the drug can help protect kidney function and reduce protein in the urine, with fewer side effects than current treatments.
Neptune City, New JerseyAges 2–18 - NCT05839314RecruitingPhase 4
Huaier granules for idiopathic membranous nephropathy with PLA2R
This trial studies whether Huaier granules can improve kidney disease activity in people with “idiopathic membranous nephropathy” who test positive for PLA2R antibodies and are still not in remission. Participants will also have been on standard blood-pressure/kidney-protecting treatment (called RASI) for at least 4 weeks.
Beijing, Beijing MunicipalityAges 18–75 - NCT06466135RecruitingPhase 2
Study of WAL0921 for glomerular kidney diseases
This study tests a new drug called WAL0921 for people with certain types of kidney disease. The goal is to see if it can help protect kidney function.
Los Angeles, CaliforniaAges 18–75 - NCT06760845Recruiting
Using light to diagnose kidney disease
This trial uses a special light technique (Raman spectroscopy) to help diagnose different types of kidney disease. It may provide a faster, less invasive way to understand your condition.
Jinan, ShandongAges Any age - NCT06962800RecruitingPhase 3
Study of felzartamab for adults with primary membranous nephropathy
This study tests whether felzartamab, given as an infusion, can help treat primary membranous nephropathy (a kidney disease causing protein in the urine and swelling). It may reduce protein loss and improve kidney function compared to standard care alone.
Huntsville, AlabamaAges 18–80 - NCT07541287RecruitingPhase 2
JADE101 for IgA Nephropathy Kidney Disease
This study tests whether JADE101, a new medicine, can help slow kidney damage in people with IgA nephropathy (a type of kidney disease caused by immune system problems). You'll take it alongside your current blood pressure medications for about 48 weeks.
Chula Vista, CaliforniaAges 18–60 - NCT06935357RecruitingPhase 3
Felzartamab infusions for IgA nephropathy
This study tests a new drug called Felzartamab (given as an infusion) for people with IgA nephropathy (IgAN), a kidney disease. The goal is to see if it can reduce protein leaking into urine and protect kidney function.
Little Rock, ArkansasAges 18 years+ - NCT04858724Recruiting
IgA nephropathy patient registry for long-term outcomes
This study gathers information from people with IgA nephropathy to better understand how the disease changes over time and what can be expected. The goal is to improve care and help guide future treatments.
Shanghai, Shanghai MunicipalityAges Any age - NCT07764991RecruitingPhase 2
Lactoferrin supplement for diabetic kidney disease
This study tests whether taking a lactoferrin supplement can help people with type 2 diabetes and chronic kidney disease (stage 3 or 4) by reducing protein in their urine, which is a sign of kidney damage. It may offer a new way to slow the progression of kidney disease.
CairoAges 18–75 - NCT07146906RecruitingPhase 2
Study of zigakibart for IgA nephropathy
This trial tests a new drug called zigakibart for people with IgA nephropathy, a kidney disease. It aims to see if the drug can help reduce protein in the urine and protect kidney function.
Denver, ColoradoAges 18–100 - NCT07750249Enrolling by invitationEarly Phase 1
Short-chain fatty acids for IgA nephropathy
This trial tests whether a daily supplement of short-chain fatty acids (SCFAs) can slow down kidney damage in people with IgA nephropathy. SCFAs are substances made by gut bacteria that may help reduce inflammation and protect the kidneys.
MartinAges 18 years+ - NCT06781944RecruitingPhase 3
Obinutuzumab vs standard treatment for membranous nephropathy
This trial tests a new antibody drug (obinutuzumab) against a standard treatment (cyclophosphamide plus steroids) for people with a kidney condition called primary membranous nephropathy that causes protein leakage. The goal is to see which treatment better reduces protein loss and protects kidney function.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04931537Recruiting
Testing early kidney marker tests for people with diabetes
This study looks for early warning signs in blood or other samples (using a special lab approach) to detect kidney problems sooner in people with diabetes. It may help patients and clinicians identify kidney risk earlier and follow changes over many years.
HangzhouAges 18–80 - NCT05234463Recruiting
Study links complement activity to IgA kidney disease severity
This study looks at how parts of the immune system (called complement) may relate to how severe IgA kidney disease is. It may help doctors understand disease activity better, even if the study is mainly observational.
StrasbourgAges 18 years+ - NCT04456816RecruitingPhase 2
Drug test for IgA? No—anti-PLA2R positive immune kidney disease
This Phase 2 trial studies AP1189 in people with a specific immune-related kidney disease called iMN and very high urine protein. It aims to see whether the drug is safe and tolerable and if it can reduce protein in the urine.
AarhusAges 18–85 - NCT06984406Recruiting
Beet product for kidney protection during heart procedure
This trial tests a beet-derived food product (a natural source of nitrate) to see if it can help prevent kidney damage caused by the contrast dye used during a heart procedure called PCI. It is designed for people who already have a higher risk of this kidney problem.
MoscowAges 18 years+ - NCT06982729RecruitingPhase 1
Testing YK012 for primary membranous nephropathy
This trial tests a new drug called YK012 for people with primary membranous nephropathy, a kidney disease where protein leaks into the urine. The goal is to see if this treatment can reduce protein loss and protect kidney function.
Beijing, Beijing MunicipalityAges 18–80 - NCT06573411RecruitingPhase 4
Finerenone for primary membranous nephropathy
This trial tests if finerenone, a medicine that may protect the kidneys, can help people with primary membranous nephropathy (a kidney disease that causes protein in urine). It is for adults who are already taking a standard blood pressure medicine but still have protein in their urine.
Guangzhou, GuangdongAges 18 years+ - NCT06965764Recruiting
Contrast Dye and Kidney Health Study
This study looks at how contrast dye used in imaging tests (like CT scans) can sometimes affect the kidneys. Researchers want to track patients at Sohag University Hospitals to better understand and prevent kidney injury after receiving contrast.
SohagAges 18 years+ - NCT05514015RecruitingPhase 4
Rituximab with steroids or rituximab alone for membranous kidney disease
This trial studies how well rituximab works in primary membranous nephropathy (a kidney condition) either by itself or with corticosteroids (steroids). It aims to see which approach controls protein leakage in the urine and protects kidney function.
Guangzhou, GuangdongAges 18–75 - NCT07096843RecruitingPhase 2
Study of Budoprutug for Primary Membranous Nephropathy
This trial tests an investigational drug called budoprutug for people with primary membranous nephropathy, a kidney condition. The goal is to see if the drug can reduce protein in the urine and help protect kidney function.
Denver, ColoradoAges 18–75 - NCT07157787RecruitingPhase 2
Testing a new drug for primary membranous nephropathy
This trial tests a new drug called ALXN1920 for adults with primary membranous nephropathy (PMN), a kidney disease where the immune system attacks the kidneys. It is for people at high risk of their disease getting worse, and it compares the new drug added to standard care versus standard care alone.
Loma Linda, CaliforniaAges 18–75
Hear when a new Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nephropathy?
- Yes. Clin2 currently lists 147 recruiting nephropathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nephropathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nephropathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.